PY1908892A - Composiciones anticonceptivas con efectos cardiovasculaes reducidos - Google Patents
Composiciones anticonceptivas con efectos cardiovasculaes reducidosInfo
- Publication number
- PY1908892A PY1908892A PY201901908892A PY1908892A PY1908892A PY 1908892 A PY1908892 A PY 1908892A PY 201901908892 A PY201901908892 A PY 201901908892A PY 1908892 A PY1908892 A PY 1908892A PY 1908892 A PY1908892 A PY 1908892A
- Authority
- PY
- Paraguay
- Prior art keywords
- thromboembolism
- cardiovascular effects
- reduced cardiovascular
- contraceptive compositions
- reduced
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La presente invención se refiere a un método anticonceptivo con efectos cardiovasculares reducidos, tal como riesgo reducido de tromboembolismo, tal como riesgo reducido de tromboembolismo venoso (TEV) y riesgo reducido de tromboembolismo aórtico (TEA). El método de la invención comprende adminsitrar a un mamífero hembra una cantidad de un componente estetrol en combinación con un componente progestagénico. El método tiene un perfil favorable para el tromboembolismo en comparación con los métodos actualmente disponibles que emplean anticonceptivos de la llamada segunda, tercera o cuarta generación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18155571 | 2018-02-07 | ||
| EP18160586 | 2018-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PY1908892A true PY1908892A (es) | 2019-10-15 |
Family
ID=65278388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PY201901908892A PY1908892A (es) | 2018-02-07 | 2019-02-07 | Composiciones anticonceptivas con efectos cardiovasculaes reducidos |
Country Status (20)
| Country | Link |
|---|---|
| EP (2) | EP3749327A1 (es) |
| JP (2) | JP2021513507A (es) |
| KR (1) | KR102717921B1 (es) |
| CN (2) | CN115429806A (es) |
| AU (1) | AU2019219070B2 (es) |
| CA (2) | CA3089804A1 (es) |
| CL (1) | CL2020002017A1 (es) |
| EC (1) | ECSP20054822A (es) |
| GE (2) | GEAP202215414A (es) |
| IL (1) | IL276584B2 (es) |
| JO (1) | JOP20200169A1 (es) |
| MA (1) | MA51733A (es) |
| NZ (1) | NZ766027A (es) |
| PH (1) | PH12020500601A1 (es) |
| PY (1) | PY1908892A (es) |
| SG (1) | SG11202007163WA (es) |
| TW (1) | TWI845496B (es) |
| UA (1) | UA126746C2 (es) |
| UY (1) | UY38075A (es) |
| WO (1) | WO2019154899A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3701944B1 (en) | 2015-06-18 | 2021-12-08 | Estetra SRL | Orodispersible dosage unit containing an estetrol component |
| MA44206B1 (fr) | 2015-06-18 | 2021-04-30 | Estetra Sprl | Comprimé orodispersible comprenant estetrol |
| CU24523B1 (es) | 2015-06-18 | 2021-06-08 | Estetra Sprl | Unidad de dosificación orodispersable que contiene un componente estetrol |
| LT3310345T (lt) | 2015-06-18 | 2021-06-25 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| EP3781171B1 (en) | 2018-04-19 | 2022-02-09 | Estetra SRL | Compounds and their uses for alleviating menopause-associated symptoms |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| HU231240B1 (hu) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
| WO2022248733A1 (en) | 2021-05-28 | 2022-12-01 | Neuralis Sa | Use of estetrol in treatment of respiratory infection diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4344405C2 (de) | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption |
| DK1390042T3 (da) * | 2001-05-23 | 2008-03-31 | Pantarhei Bioscience Bv | System for administration af et lægemiddel omfattende tetrahydroxyleret östrogen til anvendelse i hormonal svangerskabsforebyggelse |
| EP1535618A1 (en) * | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
| EP2432474A1 (de) * | 2009-05-22 | 2012-03-28 | Bayer Pharma Aktiengesellschaft | Arzneimittel zur oralen verabreichung, enthaltend mindestens ein estrogen und/oder mindestens ein gestagen und mindestens einen probiotischen bakterien-stamm |
| WO2012055840A1 (en) * | 2010-10-28 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders |
| DK3079671T3 (en) * | 2013-12-12 | 2017-12-11 | Donesta Bioscience B V | Orally disintegrating solid dosage unit containing an estetrol component |
| CA3178291A1 (en) * | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| KR102780201B1 (ko) | 2016-10-28 | 2025-03-12 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
-
2019
- 2019-02-07 IL IL276584A patent/IL276584B2/en unknown
- 2019-02-07 GE GEAP202215414A patent/GEAP202215414A/en unknown
- 2019-02-07 CA CA3089804A patent/CA3089804A1/en active Pending
- 2019-02-07 EP EP19703103.2A patent/EP3749327A1/en active Pending
- 2019-02-07 NZ NZ766027A patent/NZ766027A/en unknown
- 2019-02-07 AU AU2019219070A patent/AU2019219070B2/en active Active
- 2019-02-07 WO PCT/EP2019/052980 patent/WO2019154899A1/en not_active Ceased
- 2019-02-07 EP EP22199066.6A patent/EP4140489A1/en active Pending
- 2019-02-07 JP JP2020538823A patent/JP2021513507A/ja active Pending
- 2019-02-07 JO JOP/2020/0169A patent/JOP20200169A1/ar unknown
- 2019-02-07 UY UY38075A patent/UY38075A/es not_active Application Discontinuation
- 2019-02-07 PY PY201901908892A patent/PY1908892A/es unknown
- 2019-02-07 KR KR1020207025456A patent/KR102717921B1/ko active Active
- 2019-02-07 GE GEAP201915414A patent/GEP20227407B/en unknown
- 2019-02-07 MA MA051733A patent/MA51733A/fr unknown
- 2019-02-07 UA UAA202005421A patent/UA126746C2/uk unknown
- 2019-02-07 CA CA3178181A patent/CA3178181A1/en active Pending
- 2019-02-07 CN CN202211257175.1A patent/CN115429806A/zh active Pending
- 2019-02-07 SG SG11202007163WA patent/SG11202007163WA/en unknown
- 2019-02-07 CN CN201980012248.0A patent/CN111683664A/zh active Pending
- 2019-02-11 TW TW108104465A patent/TWI845496B/zh active
-
2020
- 2020-07-13 PH PH12020500601A patent/PH12020500601A1/en unknown
- 2020-07-31 CL CL2020002017A patent/CL2020002017A1/es unknown
- 2020-09-04 EC ECSENADI202054822A patent/ECSP20054822A/es unknown
-
2023
- 2023-09-28 JP JP2023168039A patent/JP7651645B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102717921B1 (ko) | 2024-10-16 |
| MA51733A (fr) | 2020-12-16 |
| IL276584A (en) | 2020-09-30 |
| GEAP202215414A (en) | 2022-04-25 |
| AU2019219070B2 (en) | 2024-12-19 |
| IL276584B2 (en) | 2024-10-01 |
| CN111683664A (zh) | 2020-09-18 |
| CL2020002017A1 (es) | 2020-12-04 |
| WO2019154899A1 (en) | 2019-08-15 |
| PH12020500601A1 (en) | 2021-05-17 |
| UY38075A (es) | 2019-10-01 |
| SG11202007163WA (en) | 2020-08-28 |
| JOP20200169A1 (ar) | 2020-07-07 |
| CA3178181A1 (en) | 2019-08-15 |
| KR20200118464A (ko) | 2020-10-15 |
| JP2024009834A (ja) | 2024-01-23 |
| JP2021513507A (ja) | 2021-05-27 |
| JP7651645B2 (ja) | 2025-03-26 |
| NZ766027A (en) | 2026-03-27 |
| ECSP20054822A (es) | 2020-12-31 |
| EP4140489A1 (en) | 2023-03-01 |
| IL276584B1 (en) | 2024-06-01 |
| CN115429806A (zh) | 2022-12-06 |
| EP3749327A1 (en) | 2020-12-16 |
| UA126746C2 (uk) | 2023-01-18 |
| AU2019219070A1 (en) | 2020-09-24 |
| GEP20227407B (en) | 2022-08-25 |
| CA3089804A1 (en) | 2019-08-15 |
| TWI845496B (zh) | 2024-06-21 |
| TW202011967A (zh) | 2020-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002017A1 (es) | Composición anticonceptiva con efectos cardiovasculares reducidos. | |
| MX2018011348A (es) | Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades. | |
| DOP2018000297A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| MX2019007586A (es) | Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares. | |
| ECSP19010079A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| CL2019000107A1 (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso.(divisional solicitud 201702014) | |
| CL2020002252A1 (es) | Formulación oftálmica. | |
| CL2017002636A1 (es) | Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
| NI201800139A (es) | Formulación farmacéutica líquida estable | |
| MX2019001298A (es) | Metodo de manejo de dismenorrea y dolor menstrual. | |
| CO2019001044A2 (es) | Composición de cannabis | |
| MX2021005801A (es) | Metodos para administrar corticosteroides. | |
| BR112017025859A2 (pt) | colocação de shunt intraocular ab externo | |
| MX2017003037A (es) | Esteroides neuroactivos, composiciones y usos de los mismos. | |
| CL2011000513A1 (es) | Metodos para reducir o inhibir la angiogenesis en un sujeto que tiene una enfermedad o condicion ocular asociada con la angiogenesis que comprende la administracion de un antagonista de tetraspanina 12(tspan12) y/o un antagonista de norrina. | |
| CO2017011046A2 (es) | Prenda absorbente con buen ajuste | |
| CL2017000317A1 (es) | Terapia adjuntiva con 25-hidroxi vitamina d | |
| PE20151947A1 (es) | Reduccion de la respuesta proinflamatoria | |
| BR112017010933A2 (pt) | composição farmacêutica | |
| CL2022001021A1 (es) | Una forma de dosificación parenteral estable de acetato de cetrorelix | |
| MX385405B (es) | Composición inyectable en el vítreo de un ojo que comprende un inhibidor de cinasa y el uso de la misma para tratar una enfermedad ocular. | |
| CO2020005366A2 (es) | Composición plaguicida que contiene tidiazurón y ácido poliglutámico | |
| MX2022003398A (es) | Composicion micelar inmunoestimulante. | |
| CL2017002967A1 (es) | Beta-caseinas a2 y capacidad antioxidante. | |
| AR089114A1 (es) | PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3 |